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Edited by Beat ImhofAbstract Cell adhesion mediated by the integrin a4b1 plays a
key role in many biological processes reﬂecting both the number
and functional signiﬁcance of a4b1 ligands. The lipopolysaccha-
ride (LPS) receptor, CD14, is a GPI-linked cell surface glyco-
protein with a wide range of reported functions and
associations, some of which overlap with that of a4b1. This over-
lap led us to test the speciﬁc hypothesis that a4b1 and CD14
interact directly. Jurkat T cells (a4b1+) were found to adhere
to a recombinant CD14-Fc protein via a4b1, whilst K562 cells
(a4b1) did not. However, stable reexpression of the a4-subunit
conferred this ability. The adhesion of both cell types to CD14
displayed activation state-dependent binding very similar to the
interaction of a4b1 with its prototypic ligand, VCAM-1. In so-
lid-phase assays, CD14-Fc bound to aﬃnity-puriﬁed a4b1 in a
dose-dependent manner that was induced by activating anti-b1
mAbs. Finally, in related experiments, JY cells (a4b7+) were
also found to attach to CD14-Fc in an a4-dependent manner.
In summary, CD14 is a novel ligand for a4b1, exhibiting similar
activation-state dependent binding characteristics as other a4b1
ligands. The biological relevance of this interaction will be the
subject of further studies.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Integrins are a,b heterodimeric cell surface adhesion recep-
tors that mediate cell–cell and cell–matrix interactions [1]. A
major functional role of integrins is environmental sensing,
which they achieve through the spatiotemporal control of cell
signalling at cell adhesion contacts. Current models of integrin
function envisage conformational changes occurring between
and/or within the integrin subunits that lead to altered receptor
activation states. Conformational changes induced by extracel-
lular ligand binding or cytoplasmic factors are known as ‘out-
side-in’ and ‘inside-out’ activation, respectively [2,3]. The
bidirectional responsiveness of integrins therefore allows themAbbreviations: mAb, monoclonal antibody; VCAM-1, vascular cell
adhesion molecule; MAdCAM-1, mucosal addressin cell adhesion
molecule-1; FN, ﬁbronectin; FNIII(6–10), recombinant fragment of FN
comprising type III repeats 6–10; HBS, HEPES-buﬀered saline; LPS,
lipopolysaccharide; TPA, phorbol 12-myristate 13-acetate
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doi:10.1016/j.febslet.2007.01.038to regulate the strengthening of cell–matrix interactions and to
initiate new cell adhesion contacts [4].
Integrins bind to all of their characterised ligands via a crit-
ical acidic motif in a divalent cation-dependent manner [5].
The a4b1 integrin (also known as VLA-4 or CD49d/CD29)
is expressed on the surface of a variety of cell types, including
lymphocytes, monocytes, eosinophils and basophils [6], and
has so far been reported to bind to a wide variety of cell sur-
face and extracellular matrix ligands [7] making it one of the
more promiscuous integrins. These binding partners include
the classical a4b1 ligands, vascular cell adhesion molecule
(VCAM-1) [8] and the alternatively spliced type III connecting
segment of ﬁbronectin (FN) [9,10], together with mucosal
addressin cell adhesion molecule-1 (MAdCAM-1) [11], osteo-
pontin [12], and thrombospondin [13]. Through these interac-
tions, a4b1 plays an important role in embryonic development,
adult homeostasis, and immune responses [6,14].
CD14 is a 55 kDa GPI-anchored, leucine-rich repeat (LRR)
protein [15–17]. CD14 is expressed strongly on the surface of
monocytes and other myeloid cells, and is expressed at lower
levels on B-lymphocytes, basophils, mammary cells, placental
trophoblasts, gingival ﬁbroblasts [18] and low passage number
endothelial cells [19,20]. A soluble form of CD14 is also present
in serum at lg/ml levels. CD14 is the major receptor for bacte-
rial endotoxin (lipopolysaccharide, LPS) and mediates innate
immune responses [21,22]. The interaction of LPS with CD14
results in the release of inﬂammatory cytokines and the upreg-
ulation of adhesion molecules (b1 integrin and aLb2) [21]. As
CD14 does not possess a transmembrane domain, it is envis-
aged that signals arising from the LPS/CD14 interaction
require a signalling partner to elicit a response. The Toll-like
receptors, CD55 and integrins have all been suggested to fulﬁl
this role indirectly through the formation of activation clusters
[23]. CD14 is known to have other functions, such as the phago-
cytosis of apoptotic cells [24], and this has also been postulated
to be mediated via an integrin signalling partner [25]. In sup-
port of the role of integrins in such processes, CD14 has been
reported to be in close proximity to aMb2 by resonance energy
transfer techniques, although in an LPS-dependent manner
[26]. In addition, studies have shown that an unidentiﬁed
50 kDa protein on the surface of endothelial cells can support
a4-mediated cell adhesion [27], and CD14 on endothelial cells
is required for LPS-induced rolling, adhesion and transmigra-
tion of leukocytes [20]: processes that can be mediated by a4
integrins [6]. Therefore, the overlapping functions of a4b1
and CD14 in immune responses led us to investigate the possi-
bility that they might interact directly. Using a variety of
cell-based and puriﬁed protein binding assays, we ﬁnd that
CD14 can serve as a ligand for a4b1.blished by Elsevier B.V. All rights reserved.
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2.1. General reagents and cell culture
Monoclonal antibodies (mAb) used were: 12G10, mouse anti-human
integrin b1 [28]; mAb13, rat anti-human integrin b1 (a gift from K.
Yamada, NIH, Bethesda, MD, USA); TS2/16, mouse anti-human inte-
grin b1 (a gift from A. Sonnenberg, Netherlands Cancer Institute,
Amsterdam, The Netherlands); K20, mouse anti-human integrin b1
(Beckman Coulter, High Wycombe, UK); HP2/1 and 44H6, mouse
anti-human integrin a4 (Serotec, Oxford, UK); 8F2, mouse anti-
human integrin a4 (a gift from C. Morimoto, DFCI, Boston, MA,
USA); and JBS5, mouse anti-human integrin a5 (Serotec); A poly-
clonal sheep anti-human CD14 antibody (AB383) was purchased from
R& D Systems (Abingdon, UK).
The recombinant fragment of ﬁbronectin (FN) comprising type III
repeats 6–10 [FNIII(6–10)] and containing the recognition sequence
for a5b1 was puriﬁed as previously described [29], as was the control
a5b1-Fc fusion protein [30].
All cell lines were from the European Collection of Animal Cell Cul-
tures (ECACC) unless otherwise stated, passaged every 3–4 days and
cultured at 37 C and 5% CO2 in deﬁned medium as follows. COS-1
African green monkey kidney cells were cultured in Dulbecco’s mini-
mal essential medium (DMEM) with 0.11 g/l sodium pyruvate and pyr-
idoxine supplemented with 10% (v/v) foetal calf serum (FCS), 1% (v/v)
L-glutamine. Cells were detached from ﬂasks by treatment with 1·
trypsin/EDTA for 5 min for routine passaging. The MOLT-4 human
lymphoblastic leukaemia suspension cell line, the K562 human chronic
myelogenous leukaemia suspension cell line, the Jurkat human T cell
lymphoblastic leukaemia suspension cell line (a gift from P. Shore,
University of Manchester), and the JY human cell line were cultured
in RPMI 1640, 10% (v/v) FCS, 1% (v/v) L-glutamine. An addition of
1 mg/ml G418 (GIBCO BRL) was made for cells transfected with
the appropriate expression vector.
2.2. Transfection of K562 cells with a4 integrin
Transfection and enrichment of K562 cells expressing the a4 integrin
subunit was as previously described [29].
2.3. Production of soluble Fc-fusion proteins
Recombinant soluble human CAM-Fc fusion proteins were pro-
duced in COS-1 cells as previously described [11]. VCAM-1-Fc com-
prises the Ig domains 1 and 2. CD14-Fc was a gift from D.
Simmons (GlaxoSmithKline, Uxbridge, UK), the protein comprising
residues T1-R335 of the mature protein [16].
2.4. Cell attachment assays
Cell attachment assays were performed as previously described [29].
Brieﬂy, 96-well plates (Costar Corning) were coated for 60–90 min
with protein ligands diluted in phosphate-buﬀered saline (PBS, GIBCO
BRL) before blocking with heat-denatured bovine serum albumin
(BSA). K562 or Jurkat cells were washed, resuspended at 1–
1.5 · 106 cells/ml, and 50 ll aliquots added to wells containing
HEPES-buﬀered saline (HBS) containing 2· ﬁnal concentration of
antibodies and/or cations for 30 min at 37 C and 5% (v/v) CO2.
Unbound cells were removed by aspiration and gentle washing. Bound
cells were ﬁxed by addition of 5% (v/v) glutaraldehyde in HBS, stained
with 0.1% (w/v) crystal violet in 200 mM methylethanesulfonic acid
(MES) pH 6 and dye eluted with 10% (v/v) acetic acid. To assess the
total number of cells added, 100%, 75%, 50%, 25% and 0% cells were
added to wells and ﬁxed by the addition of 1/10 volume of 50% (v/v)
glutaraldehyde and stained as above. Absorbance (570 nm) of each
well was measured with a multiscan plate reader.
2.5. Aﬃnity-puriﬁcation of a4b1
Puriﬁcation of a4b1, using mAb13, from MOLT-4 cells was as pre-
viously described [29].
2.6. Solid-phase receptor-ligand binding assay
Assays were performed as previously described [29]. Brieﬂy, Costar
high-binding microtitre plates (Corning Costar) were coated with a4b1
integrin (diluted 1:100 in PBS) overnight. Wells were blocked for 3 h
with 5% (w/v) BSA, 150 mM NaCl, 0.05% (w/v) NaN3, 25 mM
Tris–HCl, pH 7.4 and washed with TBS plus 1 mM MnCl2 and 0.1%(w/v) BSA (TBS-Mn). Anti-integrin antibodies at 20 lg/ml were added
to wells in TBS-Mn. To study the eﬀects of other divalent cat-
ions, MgCl2 or CaCl2 replaced MnCl2 in this buﬀer. A range of
CD14-Fc concentrations in TBS-Mn was also added to wells and
plates incubated at 37 C for 3 h. After washing (TBS-Mn), bound
CD14-Fc was detected with horseradish peroxidase-conjugated anti-
human-Fc antibody (Sigma) and ABTS substrate with absorbance
readings at 405 nm measured using a multiscan plate reader. Back-
ground attachment to BSA-blocked wells was subtracted from all mea-
surements.3. Results
3.1. Cells attach to CD14 via the integrin a4b1
To ascertain whether cells expressing a4b1 could adhere to
CD14, Jurkat cells were incubated with CD14-Fc-coated 96-
well plates. Cells adhered in a dose-dependent manner in the
presence of 1 mM Mn2+, with maximal adhesion observed at
a concentration of 10 lg/ml of CD14-Fc (Fig. 1A). The anti-
functional anti-a4 (HP2/1) and anti-b1 (mAb13) mAbs inhib-
ited Jurkat cell attachment compared to the non-functional
anti-a4 (44H6) and anti-b1 (K20) mAbs. Thus, attachment
to CD14-Fc was demonstrated to be mediated by a4b1
(Fig. 1B).
The K562 cell line does not express the a4-subunit, but does
express a5b1. K562 cells therefore adhere to a5b1 ligands,
such as a 50 kDa fragment of FN, but do not adhere to
a4b1 ligands, such as VCAM-1 (Fig. 2A). Consistent with
the data from Jurkat cell adhesion studies, K562 cells did
not attach to CD14-Fc (Fig. 2A). We therefore tested whether
expression of a4 on K562 cells could confer the ability to
interact with CD14-Fc via a4b1. K562 cells expressing a4
(K562-a4) attached to both VCAM-1-Fc and CD14-Fc in an
a4b1-dependent manner, in the presence of 1 mM Mn2+, as
demonstrated by addition of anti-functional mAbs directed
against the a4 subunit (Fig. 2B). K562-a4 cells also attached
to CD14-Fc in a dose-dependent manner (Fig. 2C). Both
K562-a4 and Jurkat cells did not adhere to a control Fc-fusion
protein comprising the extracellular domains of a5b1 (less
than 5% of the added cells attached at 10 lg/ml; data not
shown).
3.2. Cell attachment to CD14 via a4b1 is activation
state-dependent
Integrin-mediated adhesive events can be modulated by
mAbs and/or divalent cations. We therefore investigated the
activation state-dependence of a4b1-mediated adhesion to
CD14-Fc. Jurkat cell attachment performed in HBS only, or
in HBS supplemented with 1 mM Mg2+ and 1 mM Ca2+,
resulted in basal levels of cell attachment to CD14-Fc
(Fig. 3A). Cell attachment assays performed in 1 mM Mn2+,
however, resulted in augmented cell attachment. Identical
results were obtained for the a4b1 ligand VCAM-1-Fc (data
not shown). This is consistent with the previously characterised
eﬀects of these cations on integrin function.
The anti-b1 mAbs 12G10 and TS2/16 are well-characterised
activating anti-integrin mAbs. Cell attachment assays per-
formed in HBS+Mg2+/Ca2+ in the presence of either 12G10
or TS2/16 demonstrated increased levels of cell attachment
to CD14-Fc, comparable to that induced by Mn2+ (Fig. 3A).
This eﬀect was not seen in the presence of the non-functional
anti-b1 mAb, K20. The equivalent experiments performed in
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Fig. 2. K562-a4 cells attach to CD14-Fc via a4b1. (A) Untransfected
K562 cells and (B) K562-a4 cells were allowed to attach to 3 lg/ml
VCAM-1-Fc, CD14-Fc or FNIII(6–10) only (black bars), or in the
presence of HP2/1 (anti-functional anti-a4 mAb; white bars), 44H6
(non-functional anti-a4 mAb; light grey bars) or JBS5 (anti-functional
anti-a5 mAb; dark grey bars). (C) Untransfected K562 cells (open
circles) and K562-a4 cells (ﬁlled circles) were allowed to attach to a
range of concentrations of CD14-Fc. Assays were performed in buﬀers
containing 1 mM Mn2+. Data points represent means ± S.D.
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Fig. 1. Jurkat cells attach to CD14-Fc via a4b1. Jurkat cells expressing
endogenous a4b1 were allowed to attach to (A) a range of concen-
trations of CD14-Fc or (B) 3 lg/ml CD14-Fc in the presence of HP2/1
(anti-functional anti-a4 mAb), 44H6 (non-functional anti-a4 mAb),
mAb13 (anti-functional anti-b1 mAb) or K20 (non-functional anti-b1
mAb). Assays were performed in buﬀers containing 1 mMMn2+. Data
points represent means ± S.D.
J.D. Humphries, M.J. Humphries / FEBS Letters 581 (2007) 757–763 759HBS + Mn2+ did not produce such dramatic increases in cell
attachment, reﬂecting the already increased activation state
of the integrin due to the presence of Mn2+. Identical results
were obtained for the a4b1 ligand VCAM-1-Fc (data not
shown).
Phorbol esters, such as phorbol 12-myristate 13-acetate
(TPA), have been demonstrated to enhance integrin-mediated
adhesive events through stimulating clustering or receptor
delivery, i.e. by a mechanism that does not involve the modu-
lation of the aﬃnity of the integrin for its ligand. We therefore
investigated whether a4b1-mediated cell adhesion to CD14-Fc
could be modulated by TPA. Jurkat cell attachment to CD14-
Fc in the presence of TPA was signiﬁcantly enhanced. The
anti-functional mAb HP2/1 completely inhibited cell adhesion
under these conditions unlike the non-functional mAb 44H6,demonstrating that the cell attachment was mediated by
a4b1 (Fig. 3B).
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Fig. 3. Activation-state dependence of cell attachment to CD14-Fc.
(A) Jurkat cells were allowed to attach to 10 lg/ml CD14-Fc alone
(black bars), or in the presence of 12G10 (activating anti-b1 mAb;
white bars), TS2-16 (activating anti-b1 mAb; light grey bars) or K20
(non-functional anti-b1 mAb; dark grey bars). Divalent cation
conditions (1 mM each) are indicated below the x-axis. (B) Jurkat
cells were allowed to attach to CD14-Fc (10 lg/ml) in DMEM/HEPES
plus 0.5 mM Mn2+ alone (black bar), or in the presence of TPA at
50 ng/ml (white bar), or TPA plus HP2/1 (anti-functional anti-a4 mAb;
light grey bar), or TPA plus 44H6 (non-functional anti-a4 mAb; dark
grey bar). Data points represent means ± S.D.
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Fig. 4. Aﬃnity puriﬁed a4b1 binds to CD14-Fc in an activation state-
dependent manner. (A) Dose dependency of soluble CD14-Fc binding
to aﬃnity-puriﬁed a4b1 immobilised on a 96-well plate. (B) Soluble
CD14-Fc at 10 lg/ml was allowed to bind to immobilised a4b1 alone
(black bars), or in the presence of 12G10 (activating anti-b1 mAb;
white bars), TS2-16 (activating anti-b1 mAb; light grey bars) or 5 mM
EDTA (divalent cation chelator; dark grey bars). Divalent cation
conditions are indicated below the x-axis (2 mM each). (C) Aﬃnity
puriﬁed a4b1 was allowed to bind to immobilised CD14-Fc plus 2 mM
Mn2+ alone (black bar), or in the additional presence of 5 mM EDTA
(divalent cation chelator; white bar) or HP2/1 (anti-functional anti-a4
mAb; grey bar). Bound a4b1 was detected by the non-functional anti-
a4 mAb 44H6. Data points represent means ± S.D.
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To test for a direct a4b1/CD14-Fc interaction, the ability of
aﬃnity-puriﬁed a4b1 from MOLT-4 cells to bind to CD14-Fc
was assessed in a solid phase assay format. CD14-Fc bound to
aﬃnity-puriﬁed a4b1, coated onto the surface of 96-well
plates, in a dose-dependent manner in the presence of Mn2+
(Fig. 4A). This interaction was inhibited by chelation of diva-
lent cations with EDTA, and augmented by the activating anti-
b1 mAbs 12G10 and TS2/16 (Fig. 4B). Marked stimulation
of CD14-Fc binding to puriﬁed a4b1 by 12G10, was also
observed in 1 mM Mg2+/Ca2+ (Fig. 4B). The CD14-Fc/a4b1
interaction was also observed in an inverted assay format,
i.e. CD14-Fc being coated on the plate and subsequent incuba-
tion with a4b1 in solution. Binding of a4b1 to CD14-Fc wasagain inhibited by EDTA and HP2/1 (Fig. 4C). The a4b1
ligand VCAM-1-Fc behaved in a similar manner to CD14-Fc
in all of these assays (data not shown). Taken together, these
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can interact directly in a manner that resembles other a4b1
ligands.
3.4. LPS does not modulate Jurkat cell attachment to CD14-Fc
LPS is a well-characterised ligand for CD14. We therefore
sought to investigate whether LPS binding to CD14-Fc mod-
ulated the ability of Jurkat cells to attach to CD14-Fc via
a4b1. Cell attachment assays performed in the presence of a
range of concentrations of LPS did not alter Jurkat cell attach-
ment to CD14-Fc (Fig. 5). Furthermore, an antibody that spe-
ciﬁcally inhibits the interaction of CD14 with LPS (as
measured by the ability to inhibit LPS-induced TNF-a release
from cells) had no eﬀect on either Jurkat or K562-a4 cell
attachment to CD14-Fc or VCAM-1-Fc (data not shown).
The polyclonal anti-CD14 antibody, however, did speciﬁcally
recognise the recombinant CD14-Fc protein immobilised to
plastic in an ELISA type assay (data not shown). Taken to-
gether, these ﬁndings indicate that LPS does not modulate cell
attachment to CD14, and suggest that the region of CD14-Fc
responsible for the interaction with LPS and a4b1 are not the
same.
3.5. CD14-Fc is also a ligand for a4b7
The a4b1 and a4b7 integrins are able to bind to common
ligands such as VCAM-1 and MAdCAM-1. We therefore
investigated whether a4b7 could use CD14 as a ligand in cell
attachment assays. The a4b7+/a4b1 JY cell line attached to
CD14-Fc in a dose-dependent manner with approximately
50% of added cells being adherent to 10 lg/ml of coated
CD14-Fc (data not shown). The anti-functional anti-b1
mAb, mAb13, did not inhibit cell attachment, consistent with
these cells not expressing the b1-subunit. The anti-functional
anti-a4 mAb, HP2/1, virtually ablated JY cell attachment to
CD14-Fc, in contrast to the minor eﬀects of the non-functional
anti-a4 mAbs, 44H6 and 8F2 (Fig. 6).0 5 10 15 20 25 30
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Fig. 5. LPS modulation of Jurkat cell attachment to CD14-Fc. Jurkat
cells were allowed to attach to a range of concentrations CD14-Fc in
the presence of 1 mM Mn2+, 0.25% normal human serum and a range
of concentrations of LPS (0 lg/ml closed circles; 0.2 lg/ml open circles;
2 lg/ml closed triangles; and 20 lg/ml open triangles) from E. coli
0111:B4. Data points represent means ± S.D.4. Discussion
The main ﬁndings from these studies are that CD14 is a no-
vel ligand for a4b1, and that this interaction has similar activa-
tion-state dependent binding characteristics as other a4b1
ligands, such as VCAM-1. The CD14-a4b1 interaction was
observed in cell attachment assays with Jurkat cells that
express endogenous a4b1 and in K562 cells transfected with
the a4-subunit, but not in untransfected K562 cells. The direct
nature of this interaction was veriﬁed by protein–protein solid
phase assays and together with the ability of anti-functional
anti-a4 mAbs to perturb the adhesion, these ﬁndings demon-
strate that the interaction of the cells with CD14 is via a4b1.
It may be speculated that the integrins a4b7 and a9b1, which
interact with many of the same ligands as a4b1, could also
bind CD14. In support of this hypothesis, we have presented
data for the a4b7-expressing JY cell line, indicating that cell
surface a4b7 can also serve as a receptor for CD14.
CD14 is a receptor for bacterial lipopolysaccharide (LPS)
and as such is involved in the innate immune response. Recog-
nition of LPS by the innate immune system elicits pro-
inﬂammatory responses, e.g. the release of cytokines and
upregulation of adhesion molecules such as b1-integrins and
aLb2, which can eventually cause fatal sepsis syndrome in
humans [21,22]. As CD14 does not possess a transmembrane
domain, it is not capable of initiating a classical transmem-
brane signal. Indirect interactions of CD14 with integrins or
Toll-like receptors (TLRs) have therefore been suggested to
fulﬁl these signalling functions via complex cytoplasmic signal-
ling pathways that include the phosphorylation of focal
762 J.D. Humphries, M.J. Humphries / FEBS Letters 581 (2007) 757–763adhesion-associated proteins such as paxillin and Pyk2 [31].
Recently, the recruitment of CD14 into signalling complexes
within lipid raft domains has been suggested as an alternative
signalling mechanism [23,32]. An interesting corollary of these
data was the identiﬁcation of the a4b1-binding partner CD81
in lipid rafts, and lipid rafts have been shown to regulate the
function of a4b1 [33]. Other functions for CD14 have been
demonstrated, including LPS-mediated bone resorption, the
regulation of apoptosis and internalisation of apoptotic
bodies, and an involvement in leukocyte–endothelial cell inter-
actions [20,21,34]. The a4b1/CD14 interaction deﬁned here
may play a role in any of the above processes, and further
work will be required to assess this possibility.
Key questions still remain regarding the mechanism of bind-
ing of CD14 to a4b1 and the physiological consequences of
this interaction. The LRR has been implicated as a protein rec-
ognition motif, which typically adopts a horseshoe-like struc-
ture. Residues comprising the concave face and adjacent
loops of the structure are most commonly implicated as the
protein interaction surfaces [35]. There are precedents for the
interaction of integrins with LRR proteins, e.g. decorin/a2b1
[36] and CD14/aMb2 [37]. Also the structure of the LRR-con-
taining platelet glycoprotein Iba N-terminal domain has been
solved that is known to interact with the A1 domain of von
Willebrand factor [38]. A-domains are also found in integrins
and are involved in ligand binding, suggesting a link between
integrin-ligand binding and LRR-containing proteins. An
acidic residue is required for the cation-dependent interaction
of integrins with their ligands, and the CD14 protein contains
many (>15) conserved acidic residues between human and
mouse [15]. Some of these residues are found within the
LRR repeats and may be structurally important. Future site-
directed mutagenesis experiments targeting these residues
may aid in the identiﬁcation of key residues involved with
the interaction with a4b1. The binding site for CD14 with
LPS has been identiﬁed in the N-terminal region of the
CD14 protein [21]. This site does not appear to involve the
same residues as the site for interaction with a4b1, as a
polyclonal antibody directed against CD14 that inhibits LPS-
induced TNF-a release did not inhibit the interaction of
a4b1-expressing cells with CD14 and the presence of LPS
did not modulate a4b1-mediated cell attachment to CD14-Fc.
Soluble CD14 has been reported to interact with an unknown
membrane protein on monocytes resulting in the release of
pro-inﬂammatory cytokines such as TNF-a [18]. A simple
hypothesis was therefore that a4b1 is the unknown membrane
receptor that interacts with CD14 to produce TNF-a. This is
not the case as anti-functional mAbs that disrupt the a4b1–
CD14 interaction do not inhibit the CD14-induced release of
TNFa from monocytes (data not shown). However, the cell
attachment of THP-1 cells to CD14-Fc in these studies was
not inhibited by anti-functional a4 mAbs, suggesting that these
cells did not use a4b1 to attach to CD14. Jurkat cells that do
use a4b1 to adhere to CD14 did not release TNF-a upon incu-
bation with CD14-Fc. As Jurkat is a T cell line it may be perti-
nent to assess the modulation of CD14-induced release of other
cytokines, such as IFN-c, by a4b1.
The putative role of the interaction of a4b1 with CD14 in the
innate response may therefore be more complex. It is not
known whether the a4b1–CD14 interaction occurs in cis, i.e.
on the surface of the same cell, or in trans, between diﬀerent
cells. Another simple hypothesis could be that the interactionof CD14 with a4b1 simply tethers CD14 close to the cell mem-
brane thereby increasing the local concentration of CD14/LPS
in the vicinity of signalling molecules such as the TLRs. Such a
mechanism could involve a role for compartmentalisation of
these proteins at the cell surface by lipid rafts. LPS and many
other molecules have therefore been the focus of drug discov-
ery programmes to aid the treatment of sepsis [39]. Furthering
our understanding of the role that the interaction of a4b1 with
CD14 plays may lead to novel strategies to address such dis-
ease processes.
Overall, these data demonstrate CD14 is a novel ligand for
a4b1, and that this interaction has similar activation-state
dependent binding characteristics as other a4b1 ligands, such
as VCAM-1. This ﬁnding may have implications for the role
of a4b1 as a signalling partner for CD14 in the innate immune
response, in the phagocytosis of apoptotic cells, or in the reg-
ulation of leukocyte–endothelial interactions.
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